Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLTNASDAQ:CLVSNASDAQ:DOMHNASDAQ:FBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$5.79+2.3%$6.64$5.20▼$15.60$11.12M0.9210,867 shs10,070 shsCLVSClovis Oncology$0.43$0.08▼$3.32$11.60M0.248.88 million shs1.16 million shsDOMHDominari$5.68-9.1%$4.98$0.83▼$13.58$83.16M0.57298,620 shs797,549 shsFBIOFortress Biotech$1.78-1.7%$1.76$1.33▼$2.89$52.64M1.76410,706 shs182,582 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics0.00%-5.08%-10.09%-33.84%-61.39%CLVSClovis Oncology0.00%0.00%0.00%0.00%0.00%DOMHDominari0.00%+16.87%+23.48%+3.46%+198.95%FBIOFortress Biotech0.00%-3.78%0.00%+3.49%+0.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics2.6295 of 5 stars3.25.00.00.00.01.71.3CLVSClovis OncologyN/AN/AN/AN/AN/AN/AN/AN/ADOMHDominari0.9866 of 5 stars0.03.00.00.01.92.50.6FBIOFortress Biotech2.7392 of 5 stars3.51.00.00.03.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.33Hold$50.00763.56% UpsideCLVSClovis Oncology 0.00N/AN/AN/ADOMHDominari 0.00N/AN/AN/AFBIOFortress Biotech 3.00Buy$21.001,079.78% UpsideCurrent Analyst Ratings BreakdownLatest CLVS, FBIO, DOMH, and BOLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/13/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$25.00 ➝ $20.003/25/2025BOLTBolt BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/25/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$30.00 ➝ $25.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.45N/AN/A$29.89 per share0.19CLVSClovis Oncology$148.76M0.00N/AN/A($2.15) per share0.00DOMHDominari$18.15M4.58N/AN/A$5.71 per share0.99FBIOFortress Biotech$57.67M0.91N/AN/A($0.06) per share-29.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$63.12M-$33.40N/AN/AN/A-665.56%-94.51%-59.07%8/12/2025 (Estimated)CLVSClovis Oncology-$264.52M-$1.83N/AN/AN/A-189.37%N/A-57.78%N/ADOMHDominari-$14.70M-$4.50N/A∞N/A-167.73%-91.67%-77.80%8/6/2025 (Estimated)FBIOFortress Biotech-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)Latest CLVS, FBIO, DOMH, and BOLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BOLTBolt Biotherapeutics-$6.80-$5.80+$1.00-$0.29$0.77 million$1.22 million4/15/2025Q4 2024DOMHDominariN/A$0.20N/A$0.20N/A$6.56 million3/31/2025Q4 2024FBIOFortress Biotech-$0.79-$0.26+$0.53-$0.26$16.30 million$15.12 million3/24/2025Q4 2024BOLTBolt Biotherapeutics-$7.60-$7.60N/A-$0.42$0.79 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ACLVSClovis OncologyN/AN/AN/AN/AN/ADOMHDominariN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.483.133.13CLVSClovis OncologyN/A0.140.12DOMHDominariN/A5.745.74FBIOFortress Biotech1.741.721.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CLVSClovis Oncology24.53%DOMHDominari42.48%FBIOFortress Biotech96.51%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics30.90%CLVSClovis Oncology4.40%DOMHDominari32.98%FBIOFortress Biotech27.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics901.92 million1.33 millionNot OptionableCLVSClovis OncologyN/A144.96 million138.58 millionOptionableDOMHDominari414.64 million9.81 millionNot OptionableFBIOFortress Biotech17029.57 million21.32 millionOptionableCLVS, FBIO, DOMH, and BOLT HeadlinesRecent News About These CompaniesFortress Biotech (NASDAQ:FBIO) Stock Passes Above 200-Day Moving Average - Here's WhyJune 21 at 2:55 AM | marketbeat.comJourney Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology ConferenceJune 20 at 8:30 AM | globenewswire.comDespite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain StockJune 19, 2025 | zacks.comJourney Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TVJune 9, 2025 | globenewswire.comFortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced MomentumJune 3, 2025 | zacks.comFortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average - Time to Sell?June 3, 2025 | marketbeat.comFortress Biotech Announces Closing of Sale of Subsidiary Checkpoint TherapeuticsMay 30, 2025 | globenewswire.comRoth Capital Predicts Higher Earnings for Fortress BiotechMay 24, 2025 | marketbeat.comFortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average - Should You Sell?May 24, 2025 | marketbeat.comFortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsMay 16, 2025 | finanznachrichten.deNew Strong Sell Stocks for May 16thMay 16, 2025 | zacks.comFortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2025 | zacks.comFortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsMay 15, 2025 | globenewswire.comJourney Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsMay 14, 2025 | globenewswire.comCheckpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate UpdatesMay 13, 2025 | globenewswire.comJourney Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025May 7, 2025 | globenewswire.comFortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual ConferenceMay 7, 2025 | globenewswire.comWhy Fortress Biotech, Inc.’s (FBIO) Stock Is Down 6.18%May 7, 2025 | aaii.comThis Fortress Biotech Insider Increased Their Holding By 26% Last YearApril 9, 2025 | finance.yahoo.comJourney Medical Corporation Appoints Ramsey Alloush as Chief Operating OfficerApril 1, 2025 | globenewswire.comFortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue EstimatesMarch 31, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLVS, FBIO, DOMH, and BOLT Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$5.79 +0.13 (+2.30%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.84 +0.05 (+0.93%) As of 06/20/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Clovis Oncology NASDAQ:CLVSClovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.Dominari NASDAQ:DOMH$5.68 -0.57 (-9.12%) As of 06/20/2025 04:00 PM EasternDominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.Fortress Biotech NASDAQ:FBIO$1.78 -0.03 (-1.66%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.76 -0.02 (-1.35%) As of 06/20/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
